1. 086 The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): results from reveal, a randomised, head-to-head study. Issue 6 (24th May 2018) Authors: Butzkueven, Helmut; Jeffery, Douglas; Arnold, Douglas L; Filippi, Massimo; Geurts, Jeroen JG; Dong, Qunming; Campbell, Nolan; Licata, Stephanie; Ho, Pei-Ran Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 89:Issue 6(2018) Page Start: A35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology. Issue 4 (August 2021) Authors: Hua, Le H.; Obeidat, Ahmed Z.; Amezcua, Lilyana; Cohen, Jeffrey A.; Costello, Kathleen; Dunn, Jeffrey; Gelfand, Jeffrey M.; Goldman, Myla D.; Hopkins, Sarah; Jeffery, Douglas; Krieger, Stephen; Newsome, Scott D.; Shah, Suma; Sicotte, Nancy L.; Yadav, Vijayshree; Longbrake, Erin E. Journal: Neurology Issue: Volume 11:Issue 4(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. (April 2019) Authors: Buck, Dorothea; Andlauer, Till FM; Igl, Wilmar; Wicklein, Eva-Maria; Mühlau, Mark; Weber, Frank; Köchert, Karl; Pohl, Christoph; Arnason, Barry; Comi, Giancarlo; Cook, Stuart; Filippi, Massimo; Hartung, Hans-Peter; Jeffery, Douglas; Kappos, Ludwig; Barkhof, Frederik; Edan, Gilles; Freedman, Mark ... Journal: Multiple sclerosis Issue: Volume 25:Number 4(2019) Page Start: 565 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Issue 5 (May 2018) Authors: Kapoor, Raju; Ho, Pei-Ran; Campbell, Nolan; Chang, Ih; Deykin, Aaron; Forrestal, Fiona; Lucas, Nisha; Yu, Bei; Arnold, Douglas L; Freedman, Mark S; Goldman, Myla D; Hartung, Hans-Peter; Havrdová, Eva Kubala; Jeffery, Douglas; Miller, Aaron; Sellebjerg, Finn; Cadavid, Diego; Mikol, Dan; Steiner, D... Journal: Lancet neurology Issue: Volume 17:Issue 5(2018) Page Start: 405 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. Issue 10 (20th October 2020) Authors: Butzkueven, Helmut; Licata, Stephanie; Jeffery, Douglas; Arnold, Douglas L; Filippi, Massimo; Geurts, Jeroen JG; Santra, Sourav; Campbell, Nolan; Ho, Pei-Ran Journal: BMJ open Issue: Volume 10:Issue 10(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. Issue 10 (20th October 2020) Authors: Butzkueven, Helmut; Licata, Stephanie; Jeffery, Douglas; Arnold, Douglas L; Filippi, Massimo; Geurts, Jeroen JG; Santra, Sourav; Campbell, Nolan; Ho, Pei-Ran Journal: BMJ open Issue: Volume 10:Issue 10(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. Issue 10 (20th October 2020) Authors: Butzkueven, Helmut; Licata, Stephanie; Jeffery, Douglas; Arnold, Douglas L; Filippi, Massimo; Geurts, Jeroen JG; Santra, Sourav; Campbell, Nolan; Ho, Pei-Ran Journal: BMJ open Issue: Volume 10:Issue 10(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. Issue 10 (20th October 2020) Authors: Butzkueven, Helmut; Licata, Stephanie; Jeffery, Douglas; Arnold, Douglas L; Filippi, Massimo; Geurts, Jeroen JG; Santra, Sourav; Campbell, Nolan; Ho, Pei-Ran Journal: BMJ open Issue: Volume 10:Issue 10(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. Issue 10 (20th October 2020) Authors: Butzkueven, Helmut; Licata, Stephanie; Jeffery, Douglas; Arnold, Douglas L; Filippi, Massimo; Geurts, Jeroen JG; Santra, Sourav; Campbell, Nolan; Ho, Pei-Ran Journal: BMJ open Issue: Volume 10:Issue 10(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. Issue 10 (20th October 2020) Authors: Butzkueven, Helmut; Licata, Stephanie; Jeffery, Douglas; Arnold, Douglas L; Filippi, Massimo; Geurts, Jeroen JG; Santra, Sourav; Campbell, Nolan; Ho, Pei-Ran Journal: BMJ open Issue: Volume 10:Issue 10(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗